ロード中...
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD). In 2007, HX575 (Binocrit(®)) became the first biosimilar epoetin alfa to be approved by the European Medicines Agency (EMA). The d...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739117/ https://ncbi.nlm.nih.gov/pubmed/29296077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S146147 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|